Parvus Therapeutics Inc Email Format

Biotechnology ResearchCalifornia, United States11-50 Employees

Parvus Therapeutics Inc. is a privately held biotechnology company headquartered at 256 East Grand Avenue, South San Francisco, California 94080. It focuses on autoimmune disease research and develops Navacims, a platform technology designed to direct immune regulation by inducing regulatory T cells to treat autoimmune conditions while avoiding non-specific immune suppression. The company maintains a pipeline of proprietary drug candidates in preclinical development advancing toward clinical testing for multiple autoimmune indications, led by a leadership team with experience in drug discovery, development, manufacturing, regulatory approval, and commercialization. Parvus has established collaborations to develop inflammatory bowel disease therapies based on the Navacim platform, including a collaboration with AbbVie, and it partners with National Resilience to develop and manufacture the autoimmune drug candidate PVT401 for IBD. The organization employs 11-50 people and maintains information on its website at parvustx.com.

Sign up for free to view info

Company overview Employee directory